View in EDS

Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study.

Saved in:
Bibliographic Details
Title: Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study.
Authors: Clancy CJ; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Cornely OA; Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.; Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.; German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany., Marcella SW; Global Epidemiology and Real-World Evidence, Shionogi Inc, Florham Park, NJ, USA., Nguyen ST; Medical Affairs, Shionogi Inc, Florham Park, NJ, USA., Gozalo L; Advanced Analytics, Genesis Research, Hoboken, NJ, USA., Cai B; Center of Real-World Data and Analytics, Shionogi Inc, Florham Park, NJ, USA.
Source: Infection and drug resistance [Infect Drug Resist] 2024 Oct 15; Vol. 17, pp. 4427-4443. Date of Electronic Publication: 2024 Oct 15 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101550216 Publication Model: eCollection Cited Medium: Print ISSN: 1178-6973 (Print) Linking ISSN: 11786973 NLM ISO Abbreviation: Infect Drug Resist Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39431212
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Clancy+CJ%22">Clancy CJ</searchLink>; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Cornely+OA%22">Cornely OA</searchLink>; Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.; Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), University Hospital Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany.; German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Marcella+SW%22">Marcella SW</searchLink>; Global Epidemiology and Real-World Evidence, Shionogi Inc, Florham Park, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Nguyen+ST%22">Nguyen ST</searchLink>; Medical Affairs, Shionogi Inc, Florham Park, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Gozalo+L%22">Gozalo L</searchLink>; Advanced Analytics, Genesis Research, Hoboken, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Cai+B%22">Cai B</searchLink>; Center of Real-World Data and Analytics, Shionogi Inc, Florham Park, NJ, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101550216%22">Infection and drug resistance</searchLink> [Infect Drug Resist] 2024 Oct 15; Vol. 17, pp. 4427-4443. <i>Date of Electronic Publication: </i>2024 Oct 15 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Dove+Medical+Press%22">Dove Medical Press </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>101550216 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1178-6973 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211786973%22">11786973 </searchLink><i>NLM ISO Abbreviation: </i>Infect Drug Resist <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39431212
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2147/IDR.S475462
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 4427
    Titles:
      – TitleFull: Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Clancy CJ
      – PersonEntity:
          Name:
            NameFull: Cornely OA
      – PersonEntity:
          Name:
            NameFull: Marcella SW
      – PersonEntity:
          Name:
            NameFull: Nguyen ST
      – PersonEntity:
          Name:
            NameFull: Gozalo L
      – PersonEntity:
          Name:
            NameFull: Cai B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 10
              Text: 2024 Oct 15
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 1178-6973
          Numbering:
            – Type: volume
              Value: 17
          Titles:
            – TitleFull: Infection and drug resistance
              Type: main
ResultId 1